{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T06:12:15Z","timestamp":1793686335082,"version":"4.5.1"},"reference-count":219,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970319"],"award-info":[{"award-number":["81970319"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010029","name":"Taishan Scholar Foundation of Shandong Province","doi-asserted-by":"publisher","award":["tsqn202103170"],"award-info":[{"award-number":["tsqn202103170"]}],"id":[{"id":"10.13039\/501100010029","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.phrs.2025.107879","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T06:40:47Z","timestamp":1753339247000},"page":"107879","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["IL-17 as a therapeutic target in cardiovascular diseases: Mechanistic insights and translational opportunities"],"prefix":"10.1016","volume":"219","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6609-6338","authenticated-orcid":false,"given":"Lianyue","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangjuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guipeng","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2025.107879_bib1","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adq6618","article-title":"Naturally arising memory-phenotype CD4+ T lymphocytes contain an undifferentiated population that can generate TH1, TH17, and Treg cells","volume":"10","author":"Kawajiri","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.phrs.2025.107879_bib2","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/JLB.3MR0822-761RR","article-title":"The role of \u03b3\u03b4 T17 cells in cardiovascular disease","volume":"112","author":"Ling","year":"2022","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.phrs.2025.107879_bib3","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.it.2017.01.006","article-title":"IL-17 signaling: the yin and the yang","volume":"38","author":"Amatya","year":"2017","journal-title":"Trends Immunol."},{"key":"10.1016\/j.phrs.2025.107879_bib4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41577-022-00746-9","article-title":"IL-17 and IL-17-producing cells in protection versus pathology","volume":"23","author":"Mills","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.phrs.2025.107879_bib5","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1136\/ard-2023-224479","article-title":"New biologic (Ab-IPL-IL-17) for IL-17-mediated diseases: identification of the bioactive sequence (nIL-17) for IL-17A\/F function","volume":"82","author":"Saviano","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2025.107879_bib6","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","article-title":"Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation","volume":"77","author":"Glatt","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2025.107879_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2017.06.016","article-title":"Interleukin 17A in atherosclerosis - Regulation and pathophysiologic effector function","volume":"122","author":"Nordlohne","year":"2019","journal-title":"Cytokine"},{"key":"10.1016\/j.phrs.2025.107879_bib8","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-023-01620-3","article-title":"The IL-17 family in diseases: from bench to bedside","volume":"8","author":"Huangfu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.phrs.2025.107879_bib9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.cytogfr.2024.05.001","article-title":"Unveiling the role of IL-17: therapeutic insights and cardiovascular implications","volume":"77","author":"Jiang","year":"2024","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.phrs.2025.107879_bib10","doi-asserted-by":"crossref","DOI":"10.2174\/1573403X18666220920090632","article-title":"Responses triggered by the immune system in hypertensive conditions and repercussions on target organ damage: a review","volume":"19","author":"da Silva","year":"2023","journal-title":"Curr. Cardiol. Rev."},{"key":"10.1016\/j.phrs.2025.107879_bib11","doi-asserted-by":"crossref","first-page":"8167","DOI":"10.4049\/jimmunol.0901126","article-title":"Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice","volume":"183","author":"Erbel","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2025.107879_bib12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3897\/folmed.65.e72448","article-title":"Rheumatoid arthritis and the proinflammatory cytokine IL-17","volume":"65","author":"Selimov","year":"2023","journal-title":"Folia Med."},{"key":"10.1016\/j.phrs.2025.107879_bib13","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41584-023-00984-8","article-title":"Spondyloarthritis with inflammatory bowel disease: the latest on biologic and targeted therapies","volume":"19","author":"Cozzi","year":"2023","journal-title":"Nat. Rev. Rheuma"},{"key":"10.1016\/j.phrs.2025.107879_bib14","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","article-title":"Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials","volume":"403","author":"Kimball","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2025.107879_bib15","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s13555-024-01162-8","article-title":"Brodalumab: 5-year US pharmacovigilance report","volume":"14","author":"Lebwohl","year":"2024","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.phrs.2025.107879_bib16","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrcardio.2015.169","article-title":"Regulatory T cells in cardiovascular diseases","volume":"13","author":"Meng","year":"2016","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.phrs.2025.107879_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102429","article-title":"Critical role of interleukin (IL)-17 in inflammatory and immune disorders: an updated review of the evidence focusing in controversies","volume":"19","author":"Ruiz de Morales","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.phrs.2025.107879_bib18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41392-022-00955-7","article-title":"Inflammation and atherosclerosis: signaling pathways and therapeutic intervention","volume":"7","author":"Kong","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.phrs.2025.107879_bib19","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41577-021-00584-1","article-title":"How the immune system shapes atherosclerosis: roles of innate and adaptive immunity","volume":"22","author":"Roy","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.phrs.2025.107879_bib20","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.immuni.2019.03.007","article-title":"Cytokine circuits in cardiovascular disease","volume":"50","author":"Williams","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.phrs.2025.107879_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2015.19","article-title":"The enhanced expression of IL-17-secreting T cells during the early progression of atherosclerosis in ApoE-deficient mice fed on a western-type diet","volume":"47","author":"Jeon","year":"2015","journal-title":"Exp. Mol. Med"},{"key":"10.1016\/j.phrs.2025.107879_bib22","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.4049\/jimmunol.1000116","article-title":"A critical function of Th17 proinflammatory cells in the development of atherosclerotic plaque in mice","volume":"185","author":"Gao","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2025.107879_bib23","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/ehf2.14264","article-title":"E prostanoid receptor-3 promotes oxidized low-density lipoprotein-induced human aortic smooth muscle cells inflammation","volume":"10","author":"Hu","year":"2023","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.phrs.2025.107879_bib24","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00395-010-0135-y","article-title":"Expression of IL-17A in human atherosclerotic lesions is associated with increased inflammation and plaque vulnerability","volume":"106","author":"Erbel","year":"2011","journal-title":"Basic Res Cardiol."},{"key":"10.1016\/j.phrs.2025.107879_bib25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.atherosclerosis.2022.04.011","article-title":"Differences of inflammatory cytokine profile in patients with vulnerable plaque: a coronary CTA study","volume":"350","author":"Roesner","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2025.107879_bib26","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1161\/01.CIR.0000057851.87508.28","article-title":"Multiple atherosclerotic plaque rupture in acute coronary syndrome","volume":"107","author":"Haft","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2025.107879_bib27","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.bbrc.2012.02.117","article-title":"Interleukin-17 deficiency reduced vascular inflammation and development of atherosclerosis in Western diet-induced apoE-deficient mice","volume":"420","author":"Usui","year":"2012","journal-title":"Biochem Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2025.107879_bib28","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1161\/CIRCRESAHA.111.261784","article-title":"The IL-17A\/IL-17RA axis plays a proatherogenic role via the regulation of aortic myeloid cell recruitment","volume":"110","author":"Butcher","year":"2012","journal-title":"Circ. Res."},{"key":"10.1016\/j.phrs.2025.107879_bib29","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.4049\/jimmunol.1400181","article-title":"IL-17A influences essential functions of the monocyte\/macrophage lineage and is involved in advanced murine and human atherosclerosis","volume":"193","author":"Erbel","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2025.107879_bib30","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1161\/CIRCRESAHA.115.306301","article-title":"Endothelial cell dysfunction and the pathobiology of atherosclerosis","volume":"118","author":"Gimbrone","year":"2016","journal-title":"Circ. Res."},{"key":"10.1016\/j.phrs.2025.107879_bib31","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/ptr.6870","article-title":"Paeoniflorin-6\u2019-o-benzene sulfonate (CP-25) improves vasculitis through inhibiting IL-17A\/JAK\/STAT3 signaling pathway in endothelial cells of HFD CIA rats","volume":"35","author":"Cai","year":"2021","journal-title":"Phytother. Res."},{"key":"10.1016\/j.phrs.2025.107879_bib32","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1161\/CIRCULATIONAHA.108.827618","article-title":"Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells","volume":"119","author":"Eid","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2025.107879_bib33","doi-asserted-by":"crossref","first-page":"8167","DOI":"10.4049\/jimmunol.0901126","article-title":"Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice","volume":"183","author":"Erbel","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2025.107879_bib34","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1089\/jir.2019.0034","article-title":"The biological effects of interleukin-17A on adhesion molecules expression and foam cell formation in atherosclerotic lesions","volume":"39","author":"Shiotsugu","year":"2019","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.phrs.2025.107879_bib35","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000317400","article-title":"Pro-inflammatory effects of interleukin-17A on vascular smooth muscle cells involve NAD(P)H- oxidase derived reactive oxygen species","volume":"48","author":"Pietrowski","year":"2011","journal-title":"J. Vasc. Res."},{"key":"10.1016\/j.phrs.2025.107879_bib36","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.clim.2011.07.003","article-title":"IL-17 induces apoptosis of vascular endothelial cells: a potential mechanism for human acute coronary syndrome","volume":"141","author":"Zhu","year":"2011","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.phrs.2025.107879_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.888763","article-title":"The Th17 pathway in vascular inflammation: culprit or consort?","volume":"13","author":"Robert","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.phrs.2025.107879_bib38","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.immuni.2013.11.021","article-title":"Proatherogenic conditions promote autoimmune T helper 17 cell responses in vivo","volume":"40","author":"Lim","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.phrs.2025.107879_bib39","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003976","article-title":"Oxidized low-density lipoprotein (OxLDL)-treated dendritic cells promote activation of T cells in human atherosclerotic plaque and blood, which is repressed by statins: microRNA let-7c is integral to the effect","volume":"5","author":"Frosteg\u00e5rd","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.phrs.2025.107879_bib40","article-title":"IL-17A facilitates platelet function through the ERK2 signaling pathway in patients with acute coronary syndrome","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2025.107879_bib41","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.intimp.2018.02.006","article-title":"IL-17A promotes the formation of deep vein thrombosis in a mouse model","volume":"57","author":"Ding","year":"2018","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.phrs.2025.107879_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2022.152220","article-title":"Interleukin 17, the double-edged sword in atherosclerosis","volume":"227","author":"Moeinafshar","year":"2022","journal-title":"Immunobiology"},{"key":"10.1016\/j.phrs.2025.107879_bib43","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1161\/ATVBAHA.111.227629","article-title":"Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein e-deficient mice","volume":"31","author":"Madhur","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.phrs.2025.107879_bib44","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1161\/ATVBAHA.111.229997","article-title":"Interleukin-17A deficiency accelerates unstable atherosclerotic plaque formation in apolipoprotein E-deficient mice","volume":"32","author":"Danzaki","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.phrs.2025.107879_bib45","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1084\/jem.20090545","article-title":"Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis","volume":"206","author":"Taleb","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.phrs.2025.107879_bib46","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/ced.14180","article-title":"Effect of biologics targeting interleukin-23\/-17 axis on subclinical atherosclerosis: results of a pilot study","volume":"45","author":"Marovt","year":"2020","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.phrs.2025.107879_bib47","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12840","article-title":"IL-17 stimulates the expression of CCL2 in cardiac myocytes via Act1\/TRAF6\/p38MAPK-dependent AP-1 activation","volume":"91","author":"Du","year":"2020","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.phrs.2025.107879_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2023.156142","article-title":"Gene polymorphism in IL17A and gene-gene interaction in the IL23R\/IL17A axis are associated with susceptibility to coronary artery disease","volume":"164","author":"Zhang","year":"2023","journal-title":"Cytokine"},{"key":"10.1016\/j.phrs.2025.107879_bib49","first-page":"35","article-title":"Association study between rs2275913 genetic polymorphism and serum levels of IL-17A with risk of coronary artery disease","volume":"9","author":"Ghaznavi","year":"2020","journal-title":"Mol. Biol. Res Commun."},{"key":"10.1016\/j.phrs.2025.107879_bib50","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.22893","article-title":"The association between IL-17A and IL-23R polymorphisms and coronary artery disease risk in a Middle Eastern Chinese population","volume":"33","author":"Zhao","year":"2019","journal-title":"J. Clin. Lab Anal."},{"key":"10.1016\/j.phrs.2025.107879_bib51","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.24404","article-title":"The relation of common inflammatory cytokines with anxiety and depression and their values in estimating cardiovascular outcomes in coronary heart disease patients","volume":"36","author":"Lu","year":"2022","journal-title":"J. Clin. Lab Anal."},{"key":"10.1016\/j.phrs.2025.107879_bib52","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/4013685","article-title":"Serum cytokine profile in relation to the severity of coronary artery disease","volume":"2017","author":"Min","year":"2017","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.phrs.2025.107879_bib53","first-page":"151","article-title":"The expression of interleukin-25 increases in human coronary artery disease and is associated with the severity of coronary stenosis","volume":"23","author":"Xu","year":"2020","journal-title":"Anatol. J. Cardiol."},{"key":"10.1016\/j.phrs.2025.107879_bib54","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1177\/2047487318778088","article-title":"Cardiac rehabilitation and symptoms of anxiety and depression after percutaneous coronary intervention","volume":"25","author":"Olsen","year":"2018","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.phrs.2025.107879_bib55","doi-asserted-by":"crossref","DOI":"10.1002\/clc.24188","article-title":"Interleukin-4 and Interleukin-17 are associated with coronary artery disease","volume":"47","author":"Wang","year":"2024","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.phrs.2025.107879_bib56","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.molimm.2019.01.008","article-title":"Role of interleukin-17 in acute myocardial infarction","volume":"107","author":"Mora-Ru\u00edz","year":"2019","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.phrs.2025.107879_bib57","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1160\/TH12-06-0425","article-title":"Neutrophils, neutrophil extracellular traps and interleukin-17 associate with the organisation of thrombi in acute myocardial infarction","volume":"109","author":"de Boer","year":"2013","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.phrs.2025.107879_bib58","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1080\/08820139.2024.2316052","article-title":"Quantitative analysis of innate lymphoid cells in patients with ST-segment elevation myocardial infarction","volume":"53","author":"Ortega-Rodriguez","year":"2024","journal-title":"Immunol. Invest"},{"key":"10.1016\/j.phrs.2025.107879_bib59","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/5692829","article-title":"Effect of interleukin-17 in the activation of monocyte subsets in patients with ST-segment elevation myocardial infarction","volume":"2020","author":"Garza-Reyes","year":"2020","journal-title":"J. Immunol. Res"},{"key":"10.1016\/j.phrs.2025.107879_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188202","article-title":"Early kinetics of serum Interleukine-17A and infarct size in patients with reperfused acute ST-elevated myocardial infarction","volume":"12","author":"Bochaton","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2025.107879_bib61","article-title":"Activation of macrophage TBK1-HIF-1\u03b1-mediated IL-17\/IL-10 signaling by hyperglycemia aggravates the complexity of coronary atherosclerosis: an in vivo and in vitro study","volume":"35","author":"Li","year":"2021","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2025.107879_bib62","first-page":"5283","article-title":"Telmisartan reduces arrhythmias through increasing cardiac connexin43 by inhibiting IL-17 after myocardial infarction in rats","volume":"21","author":"Chang","year":"2017","journal-title":"Eur. Rev. Med. Pharm. Sci."},{"key":"10.1016\/j.phrs.2025.107879_bib63","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4067\/S0716-97602012000200012","article-title":"IL-17A levels increase in the infarcted region of the left ventricle in a rat model of myocardial infarction","volume":"45","author":"\u00c1valos","year":"2012","journal-title":"Biol. Res"},{"key":"10.1016\/j.phrs.2025.107879_bib64","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1161\/CIRCHEARTFAILURE.113.000604","article-title":"Interleukin-23 deficiency leads to impaired wound healing and adverse prognosis after myocardial infarction","volume":"7","author":"Savvatis","year":"2014","journal-title":"Circ. Heart Fail"},{"key":"10.1016\/j.phrs.2025.107879_bib65","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.3390\/antiox12111944","article-title":"Inflammation in myocardial ischemia\/reperfusion injury: underlying mechanisms and therapeutic potential","volume":"12","author":"Francisco","year":"2023","journal-title":"Antioxidants"},{"key":"10.1016\/j.phrs.2025.107879_bib66","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jacc.2011.10.863","article-title":"Interleukin-17A contributes to myocardial ischemia\/reperfusion injury by regulating cardiomyocyte apoptosis and neutrophil infiltration","volume":"59","author":"Liao","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2025.107879_bib67","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1016\/j.jacc.2016.01.073","article-title":"Inflammation as a driver of adverse left ventricular remodeling after acute myocardial infarction","volume":"67","author":"Westman","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2025.107879_bib68","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s00109-014-1176-8","article-title":"IL-17A promotes ventricular remodeling after myocardial infarction","volume":"92","author":"Zhou","year":"2014","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.phrs.2025.107879_bib69","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.112.004408","article-title":"Deleterious effect of the IL-23\/IL-17A axis and \u03b3\u03b4T cells on left ventricular remodeling after myocardial infarction","volume":"1","author":"Yan","year":"2012","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.phrs.2025.107879_bib70","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1016\/j.bbamcr.2016.08.013","article-title":"Interleukin-17A mediates cardiomyocyte apoptosis through Stat3-iNOS pathway","volume":"1863","author":"Su","year":"2016","journal-title":"Biochim Biophys. Acta"},{"key":"10.1016\/j.phrs.2025.107879_bib71","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/eurheartj\/ehs263","article-title":"Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction","volume":"34","author":"Simon","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2025.107879_bib72","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s41569-023-00964-1","article-title":"Immune and inflammatory mechanisms in hypertension","volume":"21","author":"Guzik","year":"2024","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.phrs.2025.107879_bib73","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/7146290","article-title":"Circulating Th1, Th2, and Th17 levels in hypertensive patients","volume":"2017","author":"Ji","year":"2017","journal-title":"Dis. Markers"},{"key":"10.1016\/j.phrs.2025.107879_bib74","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3390\/nu15020290","article-title":"The increased risk of hypertension caused by irrational dietary pattern may be associated with Th17 cell in the middle-aged and elderly rural residents of beijing city, northern china: a 1:1 matched case-control study","volume":"15","author":"Li","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.phrs.2025.107879_bib75","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1161\/HYPERTENSIONAHA.116.07493","article-title":"Interleukin-17A regulates renal sodium transporters and renal injury in angiotensin ii-induced hypertension","volume":"68","author":"Norlander","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2025.107879_bib76","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000471900","article-title":"Interleukin 17A and toll-like receptor 4 in patients with arterial hypertension","volume":"42","author":"Simundic","year":"2017","journal-title":"Kidney Blood Press Res."},{"key":"10.1016\/j.phrs.2025.107879_bib77","doi-asserted-by":"crossref","first-page":"766","DOI":"10.4314\/ahs.v16i3.17","article-title":"Association of interleukin 17 \/ angiotensin II with refractory hypertension risk in hemodialysis patients","volume":"16","author":"Wang","year":"2016","journal-title":"Afr. Health Sci."},{"key":"10.1016\/j.phrs.2025.107879_bib78","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/jch.12612","article-title":"Elevated Serum Level of Interleukin 17 in a Population With Prehypertension","volume":"17","author":"Yao","year":"2015","journal-title":"J. Clin. Hypertens."},{"key":"10.1016\/j.phrs.2025.107879_bib79","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41593-023-01497-z","article-title":"Meningeal interleukin-17-producing T cells mediate cognitive impairment in a mouse model of salt-sensitive hypertension","volume":"27","author":"Santisteban","year":"2024","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.phrs.2025.107879_bib80","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.3390\/ijms24043959","article-title":"Neurovascular coupling in hypertension is impaired by IL-17A through oxidative stress","volume":"24","author":"Youwakim","year":"2023","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.phrs.2025.107879_bib81","doi-asserted-by":"crossref","DOI":"10.1111\/aji.13843","article-title":"The role of T cell stimulated agonistic autoantibodies to the angiotensin II type I receptor (AT1-AA) in mediating multiorgan dysfunction in IL-17 induced hypertension during pregnancy","volume":"91","author":"Hogg","year":"2024","journal-title":"Am. J. Reprod. Immunol."},{"key":"10.1016\/j.phrs.2025.107879_bib82","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1042\/CS20190682","article-title":"Interleukin-17A induces vascular remodeling of small arteries and blood pressure elevation","volume":"134","author":"Orejudo","year":"2020","journal-title":"Clin. Sci."},{"key":"10.1016\/j.phrs.2025.107879_bib83","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1161\/HYPERTENSIONAHA.113.02604","article-title":"\u03b3\u03b4T Cell-derived interleukin-17A via an interleukin-1\u03b2-dependent mechanism mediates cardiac injury and fibrosis in hypertension","volume":"64","author":"Li","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2025.107879_bib84","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1093\/cvr\/cvs422","article-title":"Interleukin-17 causes Rho-kinase-mediated endothelial dysfunction and hypertension","volume":"97","author":"Nguyen","year":"2013","journal-title":"Cardiovasc Res."},{"key":"10.1016\/j.phrs.2025.107879_bib85","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1161\/HYPERTENSIONAHA.121.18219","article-title":"IL (Interleukin)-17A acts in the brain to drive neuroinflammation, sympathetic activation, and hypertension","volume":"78","author":"Cao","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2025.107879_bib86","article-title":"Endothelial dysfunction in hypertension: current concepts and clinical implications","volume":"8","author":"Gallo","year":"2021","journal-title":"Front Med."},{"key":"10.1016\/j.phrs.2025.107879_bib87","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.029179","article-title":"CD1d-dependent natural killer t cells mediate hypertension and vascular injury through interleukin-17A","volume":"12","author":"Xiao","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.phrs.2025.107879_bib88","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11906-021-01128-7","article-title":"Interleukin 17A: key player in the pathogenesis of hypertension and a potential therapeutic target","volume":"23","author":"Davis","year":"2021","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.phrs.2025.107879_bib89","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jid.2018.10.042","article-title":"Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks","volume":"139","author":"von Stebut","year":"2019","journal-title":"J. Invest Dermatol."},{"key":"10.1016\/j.phrs.2025.107879_bib90","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1097\/HJH.0000000000002368","article-title":"Toll-like receptor 7-driven lupus autoimmunity induces hypertension and vascular alterations in mice","volume":"38","author":"Robles-Vera","year":"2020","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2025.107879_bib91","doi-asserted-by":"crossref","first-page":"10063","DOI":"10.3390\/ijms251810063","article-title":"Mechanism actions of coniferyl alcohol in improving cardiac dysfunction in renovascular hypertension studied by experimental verification and network pharmacology","volume":"25","author":"Wu","year":"2024","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.phrs.2025.107879_bib92","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.bbrc.2019.05.121","article-title":"Infiltrating T helper 17 cells in the paraventricular nucleus are pathogenic for stress-induced hypertension","volume":"515","author":"Wu","year":"2019","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.phrs.2025.107879_bib93","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jacbts.2016.07.009","article-title":"Inhibition of interleukin 17-A but not Interleukin-17F signaling lowers blood pressure and reduces end-organ inflammation in angiotensin ii-induced hypertension","volume":"1","author":"Saleh","year":"2016","journal-title":"JACC Basic Transl. Sci."},{"key":"10.1016\/j.phrs.2025.107879_bib94","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00424-022-02705-8","article-title":"Interleukin 17A infusion has no acute or long-term hypertensive action in conscious unrestrained male mice","volume":"474","author":"Thangaraj","year":"2022","journal-title":"Pflug. Arch."},{"key":"10.1016\/j.phrs.2025.107879_bib95","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1161\/ATVBAHA.112.301049","article-title":"Interleukin-6-signal transducer and activator of transcription-3 signaling mediates aortic dissections induced by angiotensin II via the T-helper lymphocyte 17-interleukin 17 axis in C57BL\/6 mice","volume":"33","author":"Ju","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.phrs.2025.107879_bib96","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1161\/HYPERTENSIONAHA.112.199265","article-title":"Interferon-\u03b3 signaling inhibition ameliorates angiotensin II-induced cardiac damage","volume":"60","author":"Mark\u00f3","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2025.107879_bib97","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1161\/HYPERTENSIONAHA.113.02620","article-title":"Deficiency of the interleukin 17\/23 axis accelerates renal injury in mice with deoxycorticosterone acetate+angiotensin ii-induced hypertension","volume":"63","author":"Krebs","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2025.107879_bib98","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1161\/HYPERTENSIONAHA.109.145094","article-title":"Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction","volume":"55","author":"Madhur","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2025.107879_bib99","doi-asserted-by":"crossref","first-page":"R353","DOI":"10.1152\/ajpregu.00051.2012","article-title":"IL-17-mediated oxidative stress is an important stimulator of AT1-AA and hypertension during pregnancy","volume":"303","author":"Dhillion","year":"2012","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.phrs.2025.107879_bib100","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1161\/ATVBAHA.114.304108","article-title":"Interleukin 17 drives vascular inflammation, endothelial dysfunction, and arterial hypertension in psoriasis-like skin disease","volume":"34","author":"Karbach","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.phrs.2025.107879_bib101","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1161\/HYPERTENSIONAHA.113.02883","article-title":"Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes","volume":"63","author":"Amador","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2025.107879_bib102","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.14038","article-title":"Chronic infusion of interleukin-17 promotes hypertension, activation of cytolytic natural killer cells, and vascular dysfunction in pregnant rats","volume":"7","author":"Travis","year":"2019","journal-title":"Physiol. Rep."},{"key":"10.1016\/j.phrs.2025.107879_bib103","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1161\/ATVBAHA.119.313336","article-title":"High Salt Intake Worsens Aortic Dissection in Mice: Involvement of IL (Interleukin)-17A-Dependent ECM (Extracellular Matrix) Metabolism","volume":"40","author":"Nishida","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.phrs.2025.107879_bib104","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.preghy.2021.02.009","article-title":"Interleukin-17 induces hypertension but does not impair cerebrovascular function in pregnant rats","volume":"24","author":"Duncan","year":"2021","journal-title":"Pregnancy Hypertens."},{"key":"10.1016\/j.phrs.2025.107879_bib105","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/6721531","article-title":"T cell-derived IL-17A induces vascular dysfunction via perivascular fibrosis formation and dysregulation of \u00b7NO\/cGMP signaling","volume":"2019","author":"Sch\u00fcler","year":"2019","journal-title":"Oxid. Med Cell Longev."},{"key":"10.1016\/j.phrs.2025.107879_bib106","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1161\/HYPERTENSIONAHA.117.09374","article-title":"Regulatory T-cell augmentation or interleukin-17 inhibition prevents calcineurin inhibitor-induced hypertension in mice","volume":"70","author":"Chiasson","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2025.107879_bib107","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3389\/fphar.2019.01015","article-title":"Interleukin 17A participates in renal inflammation associated to experimental and human hypertension","volume":"10","author":"Orejudo","year":"2019","journal-title":"Front Pharm."},{"key":"10.1016\/j.phrs.2025.107879_bib108","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/HYPERTENSIONAHA.114.04975","article-title":"Renal transporter activation during angiotensin-II hypertension is blunted in interferon-\u03b3-\/- and interleukin-17A-\/- mice","volume":"65","author":"Kamat","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2025.107879_bib109","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s12872-022-02698-3","article-title":"Elevated Th17 cell proportion, related cytokines and mRNA expression level in patients with hypertension-mediated organ damage: a case control study","volume":"22","author":"Wang","year":"2022","journal-title":"BMC Cardiovasc Disord."},{"key":"10.1016\/j.phrs.2025.107879_bib110","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/1471-2369-15-159","article-title":"The relationship between asymptomatic organ damage, and serum soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) and Interleukin-17A (IL-17A) levels in non-diabetic hypertensive patients","volume":"15","author":"Ates","year":"2014","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.phrs.2025.107879_bib111","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jacbts.2016.07.009","article-title":"Inhibition of interleukin 17-A but not Interleukin-17F signaling lowers blood pressure and reduces end-organ inflammation in angiotensin II-induced hypertension","volume":"1","author":"Saleh","year":"2016","journal-title":"JACC Basic Transl. Sci."},{"key":"10.1016\/j.phrs.2025.107879_bib112","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.92801","article-title":"A salt-sensing kinase in T lymphocytes, SGK1, drives hypertension and hypertensive end-organ damage","volume":"2","author":"Norlander","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.phrs.2025.107879_bib113","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/jama.2018.21442","article-title":"Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial","volume":"321","author":"SPRINT MIND Investigators for the SPRINT Research Group","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2025.107879_bib114","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00424-022-02705-8","article-title":"Interleukin 17A infusion has no acute or long-term hypertensive action in conscious unrestrained male mice","volume":"474","author":"Thangaraj","year":"2022","journal-title":"Pflug. Arch."},{"key":"10.1016\/j.phrs.2025.107879_bib115","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1161\/ATVBAHA.112.301049","article-title":"Interleukin-6-signal transducer and activator of transcription-3 signaling mediates aortic dissections induced by angiotensin II via the T-helper lymphocyte 17-interleukin 17 axis in C57BL\/6 mice","volume":"33","author":"Ju","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.phrs.2025.107879_bib116","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1161\/HYPERTENSIONAHA.112.199265","article-title":"Interferon-\u03b3 signaling inhibition ameliorates angiotensin II-induced cardiac damage","volume":"60","author":"Mark\u00f3","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2025.107879_bib117","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1161\/HYPERTENSIONAHA.113.02620","article-title":"Deficiency of the interleukin 17\/23 axis accelerates renal injury in mice with deoxycorticosterone acetate+angiotensin ii-induced hypertension","volume":"63","author":"Krebs","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2025.107879_bib118","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/FJC.0000000000001547","article-title":"Association of interleukin-17 inhibitors with hypertension in patients with autoimmune diseases: a systematic review and meta-analysis on randomized controlled trials","volume":"83","author":"Jiang","year":"2024","journal-title":"J. Cardiovasc Pharm."},{"key":"10.1016\/j.phrs.2025.107879_bib119","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/bjd.12110","article-title":"Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study","volume":"168","author":"Papp","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.phrs.2025.107879_bib120","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"ERASURE study group, FIXTURE study group, secukinumab in plaque psoriasis--results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2025.107879_bib121","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2015.04.011","article-title":"SCULPTURE Study Group, Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE)","volume":"73","author":"Mrowietz","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.phrs.2025.107879_bib122","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/jdv.14073","article-title":"Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial, J Eur","volume":"31","author":"Lacour","year":"2017","journal-title":"Acad. Dermatol. Venereol."},{"key":"10.1016\/j.phrs.2025.107879_bib123","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab in Crohn\u2019s disease study group, secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2025.107879_bib124","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/annrheumdis-2017-212687","article-title":"Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study","volume":"77","author":"Mease","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2025.107879_bib125","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3899\/jrheum.210912","article-title":"Secukinumab in United States biologic-na\u00efve patients with psoriatic arthritis: results from the randomized, placebo-controlled CHOICE study","volume":"49","author":"Nguyen","year":"2022","journal-title":"J. Rheuma"},{"key":"10.1016\/j.phrs.2025.107879_bib126","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2025.107879_bib127","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2025.107879_bib128","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"UNCOVER-2 and UNCOVER-3 investigators, Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2025.107879_bib129","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2025.107879_bib130","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1002\/art.38617","article-title":"A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors","volume":"66","author":"Genovese","year":"2014","journal-title":"Arthritis Rheuma"},{"key":"10.1016\/j.phrs.2025.107879_bib131","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1056\/NEJMoa1109997","article-title":"Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis","volume":"366","author":"Leonardi","year":"2012","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2025.107879_bib132","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","article-title":"Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-\u03b1 inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)","volume":"401","author":"Merola","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2025.107879_bib133","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus adalimumab in plaque psoriasis","volume":"385","author":"Warren","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2025.107879_bib134","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2025.107879_bib135","doi-asserted-by":"crossref","first-page":"912","DOI":"10.3899\/jrheum.141271","article-title":"A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexate","volume":"42","author":"Pavelka","year":"2015","journal-title":"J. Rheuma"},{"key":"10.1016\/j.phrs.2025.107879_bib136","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1136\/annrheumdis-2020-219406","article-title":"4827-006 study group, Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial","volume":"80","author":"Wei","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2025.107879_bib137","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/art.27334","article-title":"LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study","volume":"62","author":"Genovese","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.phrs.2025.107879_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2022.155823","article-title":"IL-17 upregulates MCP-1 expression via Act1 \/ TRAF6 \/ TAK1 in experimental autoimmune myocarditis","volume":"152","author":"Huang","year":"2022","journal-title":"Cytokine"},{"key":"10.1016\/j.phrs.2025.107879_bib139","doi-asserted-by":"crossref","DOI":"10.1111\/1755-5922.12477","article-title":"Fasudil exerts a cardio-protective effect on mice with coxsackievirus B3-induced acute viral myocarditis","volume":"36","author":"Dai","year":"2018","journal-title":"Cardiovasc Ther."},{"key":"10.1016\/j.phrs.2025.107879_bib140","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.4049\/jimmunol.1001718","article-title":"Th17 cells contribute to viral replication in coxsackievirus B3-induced acute viral myocarditis","volume":"185","author":"Yuan","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2025.107879_bib141","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/intimm\/dxs056","article-title":"IL-17 contributes to cardiac fibrosis following experimental autoimmune myocarditis by a PKC\u03b2\/Erk1\/2\/NF-\u03baB-dependent signaling pathway","volume":"24","author":"Liu","year":"2012","journal-title":"Int Immunol."},{"key":"10.1016\/j.phrs.2025.107879_bib142","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.intimp.2013.11.008","article-title":"Autophagy contributes to IL-17-induced plasma cell differentiation in experimental autoimmune myocarditis","volume":"18","author":"Yuan","year":"2014","journal-title":"Int Immunopharmacol."},{"key":"10.1016\/j.phrs.2025.107879_bib143","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1743-422X-8-17","article-title":"Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of coxsackievirus b3-induced viral myocarditis reduces myocardium inflammation","volume":"8","author":"Fan","year":"2011","journal-title":"Virol. J."},{"key":"10.1016\/j.phrs.2025.107879_bib144","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/eurjhf\/hfr014","article-title":"Expression of functional T-cell markers and T-cell receptor Vbeta repertoire in endomyocardial biopsies from patients presenting with acute myocarditis and dilated cardiomyopathy","volume":"13","author":"Noutsias","year":"2011","journal-title":"Eur. J. Heart Fail"},{"key":"10.1016\/j.phrs.2025.107879_bib145","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.85851","article-title":"Cardiac myosin-Th17 responses promote heart failure in human myocarditis","volume":"1","author":"Myers","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.phrs.2025.107879_bib146","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/9385472","article-title":"Continued Elevation of Plasma IL-4 and IL-17 Predicts the Progression from VMC to DCM","volume":"2020","author":"Wang","year":"2020","journal-title":"Dis. Markers"},{"key":"10.1016\/j.phrs.2025.107879_bib147","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1084\/jem.20132126","article-title":"Cardiac fibroblasts mediate IL-17A-driven inflammatory dilated cardiomyopathy","volume":"211","author":"Wu","year":"2014","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.phrs.2025.107879_bib148","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1161\/CIRCRESAHA.120.316619","article-title":"Circulating Th17 and Th22 cells are associated With CMR imaging biosignatures of diffuse myocardial interstitial remodeling in chronic coronary artery disease","volume":"127","author":"Hoffmann","year":"2020","journal-title":"Circ. Res"},{"key":"10.1016\/j.phrs.2025.107879_bib149","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1161\/CIRCRESAHA.109.213157","article-title":"Interleukin-17A is dispensable for myocarditis but essential for the progression to dilated cardiomyopathy","volume":"106","author":"Baldeviano","year":"2010","journal-title":"Circ. Res"},{"key":"10.1016\/j.phrs.2025.107879_bib150","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.cellsig.2011.10.010","article-title":"Interleukin-17A stimulates cardiac fibroblast proliferation and migration via negative regulation of the dual-specificity phosphatase MKP-1\/DUSP-1","volume":"24","author":"Valente","year":"2012","journal-title":"Cell Signal"},{"key":"10.1016\/j.phrs.2025.107879_bib151","doi-asserted-by":"crossref","first-page":"55","DOI":"10.7748\/ns.2022.e12004","article-title":"Pharmacological management of chronic heart failure","volume":"37","author":"Sampson","year":"2022","journal-title":"Nurs. Stand"},{"key":"10.1016\/j.phrs.2025.107879_bib152","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2023.131384","article-title":"Clinical characteristics and prognosis of patients with heart failure and high concentrations of interleukin-17D","volume":"396","author":"Baumhove","year":"2024","journal-title":"Int J. Cardiol."},{"key":"10.1016\/j.phrs.2025.107879_bib153","article-title":"Association of NT-proBNP and interleukin-17 levels with heart failure in elderly patients","volume":"15","author":"Li","year":"2016","journal-title":"Genet Mol. Res"},{"key":"10.1016\/j.phrs.2025.107879_bib154","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3325\/cmj.2018.59.139","article-title":"Association of levels of interleukin 17 and T-helper 17 count with symptom severity and etiology of chronic heart failure: a case-control study","volume":"59","author":"Rahmati","year":"2018","journal-title":"Croat. Med J."},{"key":"10.1016\/j.phrs.2025.107879_bib155","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1038\/s41401-020-00580-6","article-title":"Interleukin-17 upregulation participates in the pathogenesis of heart failure in mice via NF-\u03baB-dependent suppression of SERCA2a and Cav1.2 expression","volume":"42","author":"Xue","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.phrs.2025.107879_bib156","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.yjmcc.2018.08.005","article-title":"Interleukin-17 enhances cardiac ventricular remodeling via activating MAPK pathway in ischemic heart failure","volume":"122","author":"Chang","year":"2018","journal-title":"J. Mol. Cell Cardiol."},{"key":"10.1016\/j.phrs.2025.107879_bib157","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3109\/14017431.2012.699096","article-title":"Circulating Th17 cells are not elevated in patients with chronic heart failure","volume":"46","author":"Zhu","year":"2012","journal-title":"Scand. Cardiovasc J."},{"key":"10.1016\/j.phrs.2025.107879_bib158","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/eji.201847583","article-title":"Sca-1+ cardiac fibroblasts promote development of heart failure","volume":"48","author":"Chen","year":"2018","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.phrs.2025.107879_bib159","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.yexmp.2009.06.001","article-title":"IL-17 induces myocardial fibrosis and enhances RANKL\/OPG and MMP\/TIMP signaling in isoproterenol-induced heart failure","volume":"87","author":"Feng","year":"2009","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.phrs.2025.107879_bib160","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109690","article-title":"Minocycline reverses IL-17A\/TRAF3IP2-mediated p38 MAPK\/NF-\u03baB\/iNOS\/NO-dependent cardiomyocyte contractile depression and death","volume":"73","author":"Yoshida","year":"2020","journal-title":"Cell Signal"},{"key":"10.1016\/j.phrs.2025.107879_bib161","first-page":"336","article-title":"The HMGB1\u2011IL\u201117A axis contributes to hypoxia\/reoxygenation injury via regulation of cardiomyocyte apoptosis and autophagy","volume":"17","author":"Hu","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.phrs.2025.107879_bib162","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202400384R","article-title":"Blocking CTLA-4 promotes pressure overload-induced heart failure via activating Th17 cells","volume":"38","author":"Shang","year":"2024","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2025.107879_bib163","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/jphp.13181","article-title":"Sinomenine\u2019s protective role and mechanism in stress load-induced heart failure","volume":"72","author":"Fu","year":"2020","journal-title":"J. Pharm. Pharm."},{"key":"10.1016\/j.phrs.2025.107879_bib164","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.hrthm.2014.10.007","article-title":"Atherosclerosis exacerbates arrhythmia following myocardial infarction: Role of myocardial inflammation","volume":"12","author":"De Jesus","year":"2015","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.phrs.2025.107879_bib165","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s10557-020-07072-z","article-title":"Rhodiola crenulata reduces ventricular arrhythmia through mitigating the activation of IL-17 and inhibiting the MAPK signaling pathway","volume":"35","author":"Hsiao","year":"2021","journal-title":"Cardiovasc Drugs Ther."},{"key":"10.1016\/j.phrs.2025.107879_bib166","first-page":"1601","volume":"17","author":"Priori","year":"2015","journal-title":"Europace"},{"key":"10.1016\/j.phrs.2025.107879_bib167","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41401-021-00659-8","article-title":"Knockout of interleukin-17A diminishes ventricular arrhythmia susceptibility in diabetic mice via inhibiting NF-\u03baB-mediated electrical remodeling","volume":"43","author":"Li","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.phrs.2025.107879_bib168","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.032277","article-title":"Impact of obesity on atrial fibrillation pathogenesis and treatment options","volume":"13","author":"Sha","year":"2024","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.phrs.2025.107879_bib169","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nrcardio.2015.2","article-title":"Inflammation and the pathogenesis of atrial fibrillation","volume":"12","author":"Hu","year":"2015","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.phrs.2025.107879_bib170","first-page":"246","article-title":"Increased IL-17A in atrial fibrillation correlates with neutrophil to lymphocyte ratio","volume":"11","author":"Nikoo","year":"2014","journal-title":"Iran. J. Immunol."},{"key":"10.1016\/j.phrs.2025.107879_bib171","article-title":"Elevated plasma levels of Th17-related cytokines are associated with increased risk of atrial fibrillation","volume":"6","author":"Wu","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2025.107879_bib172","first-page":"432","article-title":"Interleukin-17A contributes to atrial fibrillation recurrence and left atrial reservoir function after catheter ablation","volume":"129","author":"Xu","year":"2019","journal-title":"Pol. Arch. Intern Med"},{"key":"10.1016\/j.phrs.2025.107879_bib173","first-page":"16252","article-title":"Association between interleukin 17A levels and left atrial spontaneous echo contrast in patients with nonvalvular atrial fibrillation","volume":"132","author":"Xu","year":"2022","journal-title":"Pol. Arch. Intern Med"},{"key":"10.1016\/j.phrs.2025.107879_bib174","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1742-2094-10-78","article-title":"Improved neurocognitive functions correlate with reduced inflammatory burden in atrial fibrillation patients treated with intensive cholesterol lowering therapy","volume":"10","author":"Lappeg\u00e5rd","year":"2013","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.phrs.2025.107879_bib175","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/cvr\/cvad168","article-title":"Crosstalk of platelets with macrophages and fibroblasts aggravates inflammation, aortic wall stiffening, and osteopontin release in abdominal aortic aneurysm","volume":"120","author":"Wagenh\u00e4user","year":"2024","journal-title":"Cardiovasc Res."},{"key":"10.1016\/j.phrs.2025.107879_bib176","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1161\/CIRCULATIONAHA.111.083451","article-title":"Experimental abdominal aortic aneurysm formation is mediated by IL-17 and attenuated by mesenchymal stem cell treatment","volume":"126","author":"Sharma","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2025.107879_bib177","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1161\/ATVBAHA.114.304435","article-title":"Inhibiting the Th17\/IL-17A-related inflammatory responses with digoxin confers protection against experimental abdominal aortic aneurysm","volume":"34","author":"Wei","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.phrs.2025.107879_bib178","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1161\/ATVBAHA.112.300516","article-title":"Overexpression of SOCS3 in T lymphocytes leads to impaired interleukin-17 production and severe aortic aneurysm formation in mice--brief report","volume":"33","author":"Romain","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.phrs.2025.107879_bib179","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1161\/CIRCGENETICS.111.961235","article-title":"Frequent and widespread vascular abnormalities in human signal transducer and activator of transcription 3 deficiency","volume":"5","author":"Chandesris","year":"2012","journal-title":"Circ. Cardiovasc Genet"},{"key":"10.1016\/j.phrs.2025.107879_bib180","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1159\/000510048","article-title":"In situ evidence of collagen V and interleukin-6\/interleukin-17 activation in vascular remodeling of experimental pulmonary hypertension","volume":"87","author":"Batah","year":"2020","journal-title":"Pathobiology"},{"key":"10.1016\/j.phrs.2025.107879_bib181","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S2213-2600(15)00517-2","article-title":"Hypoxic pulmonary hypertension in chronic lung diseases: novel vasoconstrictor pathways","volume":"4","author":"Rowan","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.phrs.2025.107879_bib182","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1136\/thoraxjnl-2018-211846","article-title":"Targeting IL-17 attenuates hypoxia-induced pulmonary hypertension through downregulation of \u03b2-catenin","volume":"74","author":"Wang","year":"2019","journal-title":"Thorax"},{"key":"10.1016\/j.phrs.2025.107879_bib183","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/s41569-023-00845-7","article-title":"Calcific aortic valve disease: mechanisms, prevention and treatment","volume":"20","author":"Moncla","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.phrs.2025.107879_bib184","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s11596-020-2230-0","article-title":"Role of interleukin 17A in aortic valve inflammation in apolipoprotein e-deficient mice","volume":"40","author":"Liu","year":"2020","journal-title":"Curr. Med. Sci."},{"key":"10.1016\/j.phrs.2025.107879_bib185","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.bbrc.2023.04.079","article-title":"IL-17A induces valvular endothelial inflammation and aggravates calcific aortic valve disease","volume":"672","author":"Yang","year":"2023","journal-title":"Biochem Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2025.107879_bib186","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1111\/all.14281","article-title":"IL-1\u03b2 and IL-17A are involved in IVIG resistance through activation of C\/EBP\u03b2 and \u03b4 in a coronary artery model of Kawasaki disease","volume":"75","author":"Inoue","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.phrs.2025.107879_bib187","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.939","article-title":"MiR-223-3p affects the proliferation and apoptosis of HCAECs in Kawasaki disease by regulating the expression of FOXP3","volume":"11","author":"Zheng","year":"2023","journal-title":"Immun. Inflamm. Dis."},{"key":"10.1016\/j.phrs.2025.107879_bib188","first-page":"986","article-title":"Relationship between IL-17A gene polymorphism and susceptibility to Kawasaki disease","volume":"48","author":"Yang","year":"2023","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban."},{"key":"10.1016\/j.phrs.2025.107879_bib189","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10875-024-01673-1","article-title":"Involvement of IL-17 A\/IL-17 receptor a with neutrophil recruitment and the severity of coronary arteritis in kawasaki disease","volume":"44","author":"Lin","year":"2024","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.phrs.2025.107879_bib190","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00296-022-05186-1","article-title":"Association of immunological parameters with aortic dilatation in giant cell arteritis: a cross-sectional study","volume":"43","author":"Jud","year":"2023","journal-title":"Rheuma Int"},{"key":"10.1016\/j.phrs.2025.107879_bib191","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.autrev.2010.05.002","article-title":"Pathogenesis of giant cell arteritis: More than just an inflammatory condition?","volume":"9","author":"Ly","year":"2010","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.phrs.2025.107879_bib192","first-page":"816","article-title":"Low relapse rate in patients with giant cell arteritis in a multi-centre retrospective Turkish Registry","volume":"42","author":"Alibaz-\u00d6ner","year":"2024","journal-title":"Clin. Exp. Rheuma"},{"key":"10.1016\/j.phrs.2025.107879_bib193","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1136\/annrheumdis-2014-205261","article-title":"Influence of the IL17A locus in giant cell arteritis susceptibility","volume":"73","author":"M\u00e1rquez","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2025.107879_bib194","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1161\/CIRCULATIONAHA.109.872903","article-title":"Th17 and Th1 T-cell responses in giant cell arteritis","volume":"121","author":"Deng","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2025.107879_bib195","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1136\/annrheumdis-2012-201836","article-title":"Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis","volume":"72","author":"Esp\u00edgol-Frigol\u00e9","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2025.107879_bib196","article-title":"The IL-17 pathway as a target in giant cell arteritis","volume":"14","author":"Zeisbrich","year":"2023","journal-title":"Front Immunol."},{"key":"10.1016\/j.phrs.2025.107879_bib197","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1016\/S2665-9913(23)00101-7","article-title":"Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"5","author":"Venhoff","year":"2023","journal-title":"Lancet Rheuma"},{"key":"10.1016\/j.phrs.2025.107879_bib198","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1174249","article-title":"Arterial wall fibrosis in Takayasu arteritis and its potential for therapeutic modulation","volume":"14","author":"Misra","year":"2023","journal-title":"Front Immunol."},{"key":"10.1016\/j.phrs.2025.107879_bib199","article-title":"Increased circulating Th17 cells, serum IL-17A, and IL-23 in takayasu arteritis","volume":"2016","author":"Misra","year":"2016","journal-title":"Autoimmune Dis."},{"key":"10.1016\/j.phrs.2025.107879_bib200","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s13075-016-1193-9","article-title":"Fewer subsequent relapses and lower levels of IL-17 in Takayasu arteritis developed after the age of 40 years","volume":"18","author":"Fukui","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.phrs.2025.107879_bib201","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0001-7310(14)70014-6","article-title":"Pathogenic role of IL-17 in psoriasis and psoriatic arthritis","volume":"105 1","author":"Chiricozzi","year":"2014","journal-title":"Actas Dermosifiliogr."},{"key":"10.1016\/j.phrs.2025.107879_bib202","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1165\/ajrcmb.25.3.4424","article-title":"Interleukin-17 and lung host defense against Klebsiella pneumoniae infection","volume":"25","author":"Ye","year":"2001","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.phrs.2025.107879_bib203","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1084\/jem.194.4.519","article-title":"Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense","volume":"194","author":"Ye","year":"2001","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.phrs.2025.107879_bib204","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.3390\/jcm13133864","article-title":"Long-term persistence rate of secukinumab in psoriatic patients: a six-year multicenter, real-world experience, retrospective study","volume":"13","author":"Galluzzo","year":"2024","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.phrs.2025.107879_bib205","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40744-020-00261-0","article-title":"Efficacy and safety of ixekizumab in patients with psoriatic arthritis and inadequate response to TNF inhibitors: 3-year follow-up (SPIRIT-P2)","volume":"8","author":"Orbai","year":"2021","journal-title":"Rheuma Ther."},{"key":"10.1016\/j.phrs.2025.107879_bib206","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3899\/jrheum.170429","article-title":"Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52-week results from a phase III study (SPIRIT-P1)","volume":"45","author":"van der Heijde","year":"2018","journal-title":"J. Rheuma"},{"key":"10.1016\/j.phrs.2025.107879_bib207","doi-asserted-by":"crossref","DOI":"10.1038\/cti.2016.71","article-title":"Chronic mucocutaneous candidiasis disease associated with inborn errors of IL-17 immunity","volume":"5","author":"Okada","year":"2016","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.phrs.2025.107879_bib208","article-title":"Risk of candidiasis associated with interleukin-17 inhibitors: a real-world observational study of multiple independent sources","volume":"13","author":"Davidson","year":"2022","journal-title":"Lancet Reg. Health Eur."},{"key":"10.1016\/j.phrs.2025.107879_bib209","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/17460441.2025.2482058","article-title":"The preclinical discovery and development of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa","volume":"20","author":"Knecht-Gurwin","year":"2025","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.phrs.2025.107879_bib210","doi-asserted-by":"crossref","first-page":"adv00698","DOI":"10.2340\/actadv.v102.563","article-title":"Long-term safety of secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: update on integrated pooled clinical trial and post-marketing surveillance data","volume":"102","author":"Gottlieb","year":"2022","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.phrs.2025.107879_bib211","doi-asserted-by":"crossref","DOI":"10.1177\/1744806918762205","article-title":"Quantitative evaluation to efficacy and safety of therapies for psoriasis: a network meta-analysis","volume":"14","author":"Lv","year":"2018","journal-title":"Mol. Pain."},{"key":"10.1016\/j.phrs.2025.107879_bib212","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.abd.2023.08.004","article-title":"Infections in the era of immunobiologicals","volume":"99","author":"Romiti","year":"2024","journal-title":"Bras. Dermatol."},{"key":"10.1016\/j.phrs.2025.107879_bib213","doi-asserted-by":"crossref","first-page":"adv00698","DOI":"10.2340\/actadv.v102.563","article-title":"Long-term safety of secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: update on integrated pooled clinical trial and post-marketing surveillance data","volume":"102","author":"Gottlieb","year":"2022","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.phrs.2025.107879_bib214","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2024.131819","article-title":"Novel anti-psoriasis agent-associated cardiotoxicity, analysis of the FDA adverse event reporting system (FAERS)","volume":"402","author":"Al-Yafeai","year":"2024","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.phrs.2025.107879_bib215","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1111\/bcp.15581","article-title":"Potential cerebrovascular accident signal for risankizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS)","volume":"89","author":"Woods","year":"2023","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.phrs.2025.107879_bib216","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/art.40579","article-title":"Phase II study of ABT-122, a tumor necrosis factor- and interleukin-17A-targeted dual variable domain immunoglobulin, in patients with psoriatic arthritis with an inadequate response to methotrexate","volume":"70","author":"Mease","year":"2018","journal-title":"Arthritis Rheuma"},{"key":"10.1016\/j.phrs.2025.107879_bib217","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1093\/rheumatology\/key173","article-title":"Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis","volume":"57","author":"Genovese","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.phrs.2025.107879_bib218","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/17460441.2025.2482058","article-title":"The preclinical discovery and development of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa","volume":"20","author":"Knecht-Gurwin","year":"2025","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.phrs.2025.107879_bib219","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1080\/14712598.2023.2215923","article-title":"Anti-IL17 treatment in childhood chronic rheumatic diseases","volume":"23","author":"Maniscalco","year":"2023","journal-title":"Expert Opin. Biol. Ther."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825003044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825003044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:18:23Z","timestamp":1772777903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661825003044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":219,"alternative-id":["S1043661825003044"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107879","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IL-17 as a therapeutic target in cardiovascular diseases: Mechanistic insights and translational opportunities","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107879","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107879"}}